Drug Profile
INCB 20817
Alternative Names: INCB20817Latest Information Update: 12 Oct 2015
Price :
$50
*
At a glance
- Originator Incyte Corporation
- Class Antihyperglycaemics
- Mechanism of Action Hydroxysteroid dehydrogenase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Type 2 diabetes mellitus
Most Recent Events
- 30 Apr 2008 Phase-I clinical trials in Type-2 diabetes mellitus in USA (PO)
- 27 Jul 2007 Preclinical trials in Type-2 diabetes mellitus in USA (unspecified route)